Malaysia’s healthcare system, skilled workforce, and diverse population presents an attractive proposition for global pharmaceutical companies looking to conduct multicentre clinical trials. In 2023, Malaysia ranked second in the Southeast Asian region in terms of the number of global industry-sponsored studies. How do we maintain our potential as a regional hub for clinical trials, especially moving up the value chain to focus more on Phase 1, or first-in-human, clinical trials? Dr Akhmal Yusof, Chief Executive Officer of Clinical Research Malaysia, and Dr Mohamed Elwakil, Country President of Novartis Malaysia, join Dr George Lee to discuss.

Image credit: Clinical Research Malaysia Facebook